+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hyperimmune Globulins Market by Route of Administration (Intramuscular, Intravenous, Subcutaneous), Application (Prophylaxis, Treatment), Product Type, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Hyperimmune Globulins Market by Route of Administration (Intramuscular, Intravenous, Subcutaneous), Application (Prophylaxis, Treatment), Product Type, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Hyperimmune Globulins Market by Route of Administration (Intramuscular, Intravenous, Subcutaneous), Application (Prophylaxis, Treatment), Product Type, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6130935
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The emergence of hyperimmune globulins as a critical therapeutic class has been propelled by their proven efficacy in preventing and treating a spectrum of infectious diseases. As global healthcare systems adapt to lessons learned from recent pandemics, the demand for targeted immunoglobulin therapies continues to rise, underscoring the need for robust supply chains, innovative formulation technologies, and streamlined regulatory pathways. Stakeholders across manufacturing, distribution, and clinical practice are now converging on a shared recognition: delivering safe, high-potency hyperimmune globulins requires coordinated efforts that balance safety, scalability, and affordability.

Moreover, evolving patient demographics and shifts in disease epidemiology are reshaping treatment paradigms. Aging populations with increased susceptibility to viral and bacterial pathogens are driving intensified research into passive immunization strategies. Parallel advances in plasma collection methodologies and purification processes are enhancing product consistency while reducing the risk of pathogen transmission. Consequently, hyperimmune globulins occupy a strategic position at the intersection of public health preparedness and personalized medicine, presenting both opportunities and challenges for manufacturers, healthcare providers, and regulatory bodies alike.

Exploring Pivotal Technological, Regulatory, and Clinical Breakthroughs Redefining Hyperimmune Globulins from Production to Patient Outcomes Over Recent Years

Breakthroughs in bioprocessing, regulatory reform, and clinical validation are collectively redefining how hyperimmune globulins are developed, produced, and deployed. Advances in high-throughput screening and monoclonal antibody enrichment have accelerated the identification of potent immunoglobulin fractions, reducing time-to-clinic while enhancing safety margins. Simultaneously, regulators have introduced accelerated approval pathways for therapies addressing unmet medical needs, incentivizing investment in next-generation plasma derivatives.

In parallel, emerging clinical data are validating novel indications and dosing regimens. Adaptive trial designs and real-world evidence initiatives are generating deeper insights into efficacy against condition-specific antigens, expanding the therapeutic scope beyond traditional prophylaxis. Furthermore, continuous manufacturing technologies and automated chromatography systems are streamlining large-scale production, offering unprecedented consistency and cost efficiency. Taken together, these technological, regulatory, and clinical shifts are ushering in a new era of precision-guided passive immunotherapies and positioning hyperimmune globulins as indispensable tools in modern healthcare.

Assessing the Comprehensive Effects of the 2025 United States Tariffs on Hyperimmune Globulin Supply Chains, Pricing Dynamics, and Global Accessibility

The introduction of new tariffs by the United States in 2025 has had far-reaching implications for hyperimmune globulin supply chains, prompting stakeholders to reassess sourcing strategies and contingency plans. Tariff adjustments on imported plasma derivatives have increased landed costs, compelling manufacturers to explore domestic plasma collection expansion or alternative low-tariff trade corridors. As a result, transportation logistics and inventory management practices have been recalibrated to mitigate cost pressures and ensure uninterrupted product flow.

Consequently, pricing dynamics have shifted, with increased production overheads being partially absorbed by value-based contracting and volume-based agreements. Healthcare providers are negotiating innovative reimbursement models to distribute cost burdens across treatment cycles and patient cohorts more equitably. Meanwhile, global accessibility has been influenced by redefined supplier relationships, with emerging economies seeking regional manufacturing partnerships to bypass tariff-induced constraints. In sum, the cumulative impact of US tariffs in 2025 has catalyzed strategic realignments, driving resilience and adaptive sourcing across the hyperimmune globulin ecosystem.

Deciphering Market Opportunities through Detailed Analysis of Routes of Administration, Applications, Product Types, Distribution Channels, and End Users

Diving into segmentation offers clarity on where hyperimmune globulin demand is most pronounced and how stakeholders can optimize offerings. In terms of route of administration, the market’s landscape includes intramuscular injections favored for rapid prophylactic dosing, intravenous infusions relied upon in severe treatment settings, and the growing subcutaneous modality that enhances patient convenience in outpatient care. When examining applications, prophylaxis use cases span Cytomegalovirus, Hepatitis B, Rabies, and Tetanus, highlighting preventive strategies for at-risk populations, while treatment applications targeting the same disease categories underscore therapeutic interventions for active infections.

From a product type perspective, equine-derived immunoglobulins maintain a crucial role in antitoxin and antivenom formulations, whereas human-sourced products deliver superior compatibility and reduced immunogenicity. Distribution channels reveal that hospital pharmacies are central to acute care supply, online pharmacies are unlocking new patient segments through digital ordering, and retail pharmacies support ongoing outpatient administration. Finally, end users encompass clinics as first-line immunization centers, home care settings emphasizing patient comfort and adherence, and hospitals that serve as pivotal hubs for high-acuity treatment protocols. Together, these segmented insights illuminate critical opportunities to tailor product development, distribution intensity, and clinical engagement strategies.

Illuminating Regional Growth Patterns and Demand Drivers for Hyperimmune Globulins across the Americas, Europe Middle East Africa, and Asia-Pacific

Regional dynamics profoundly shape hyperimmune globulin demand and stakeholder strategies. In the Americas, advanced plasma collection infrastructure and supportive regulatory frameworks underpin a mature supply base, while collaborative initiatives between public health agencies and manufacturers drive broad prophylactic campaigns. The region’s emphasis on innovation and patient-centric care models also fosters accelerated adoption of novel formulations and dose optimization studies.

Across Europe, the Middle East, and Africa, diverse healthcare systems navigate varying reimbursement landscapes and pathogen prevalence profiles. Well-established markets in Western Europe leverage centralized procurement to negotiate favorable pricing, whereas emerging markets in the Middle East and Africa are investing in local plasma fractionation capabilities to address regional public health priorities. Meanwhile, Asia-Pacific’s expansive patient populations and growing healthcare investment are creating pockets of high demand, particularly in China, Japan, and India, where government-supported immunization programs and private sector partnerships are scaling up production capacities. Collectively, these regional patterns reveal where tailored engagement and strategic partnerships can maximize impact for hyperimmune globulin stakeholders.

Evaluating Competitive Strategies, Innovations, Collaborations, and Portfolio Developments among Leading Hyperimmune Globulin Industry Participants

Leading organizations in the hyperimmune globulin landscape are differentiating through diversified portfolios, strategic alliances, and targeted R&D investments. Several prominent players are expanding their plasma center networks to secure raw material continuity while engaging in licensing agreements with biotech firms to incorporate next-generation monoclonal enrichment technologies. Collaborative research partnerships between industry and academic institutions are yielding proprietary immunoglobulin formulations optimized for specific viral strains, opening new avenues for indication expansion.

Moreover, mergers and acquisitions are reshaping competitive dynamics, enabling integrated supply chain control and end-to-end process standardization. Key participants are also leveraging digital solutions-such as blockchain-enabled traceability systems-to bolster product integrity from donor to patient. Concurrently, investments in scalable purification platforms and single-use bioreactor technologies are driving down batch variability and accelerating time to release. Collectively, these company-level initiatives underscore a commitment to innovation, resilience, and sustained growth in the hyperimmune globulin sector.

Strategic Imperatives and Operational Best Practices for Industry Leaders to Capitalize on Evolving Trends in the Hyperimmune Globulin Sector

To thrive amidst evolving industry dynamics, companies must adopt strategic imperatives that align with emerging therapeutic trends and regulatory expectations. First, enhancing plasma donor recruitment through digital engagement campaigns and mobile collection units can mitigate raw material shortages and diversify donor pools. Concurrently, forging strategic alliances with contract manufacturing organizations equipped with advanced fractionation capabilities can bolster production agility and cost efficiency.

In addition, prioritizing adaptive clinical trial frameworks and real-world evidence generation will support accelerated regulatory approvals for novel indications. Executives should also explore outcome-based contracting models that tie reimbursement to demonstrable clinical benefits, fostering shared risk and aligning incentives across the value chain. Finally, investing in digital supply chain monitoring and predictive analytics will enable proactive inventory management, reduce wastage, and enhance responsiveness to sudden demand shifts. By implementing these best practices, industry leaders can secure competitive advantage, drive sustainable growth, and deliver meaningful patient outcomes.

Methodical Approach and Analytical Frameworks Underpinning the Comprehensive Investigation of Hyperimmune Globulin Market Dynamics and Stakeholder Perspectives

This research employed a rigorous, multi-phase approach combining qualitative and quantitative methods to ensure comprehensive market insights. Primary research consisted of in-depth interviews with senior executives, clinician stakeholders, and supply chain experts to capture firsthand perspectives on production challenges, clinical adoption barriers, and emerging opportunities. Secondary research involved systematic analysis of peer-reviewed studies, regulatory filings, industry publications, and conference proceedings to validate technological trends and policy developments.

Data triangulation techniques were utilized to reconcile perspectives across sources, providing robust validation of key findings. Analytical frameworks such as SWOT and Porter’s Five Forces were applied to assess competitive intensity, supplier bargaining power, and potential disruption vectors. Regional demand assessments drew upon epidemiological data and public health program reports, while segmentation analysis integrated therapeutic application profiles with distribution and end-user behavior. This methodical process underpins the reliability and depth of the insights presented in this report.

Synthesizing Key Findings and Strategic Perspectives to Inform Future Directions and Investment Decisions in the Hyperimmune Globulin Market Landscape

In summary, hyperimmune globulins occupy a pivotal role in modern preventive and therapeutic arsenals, driven by technological innovation, evolving clinical needs, and shifting policy landscapes. Key drivers-including improved plasma collection methods, regulatory acceleration pathways, and adaptive clinical designs-have collectively enhanced product efficacy and market responsiveness. Meanwhile, segmentation analysis has illuminated targeted opportunities across administration routes, disease applications, product formats, distribution channels, and end users.

Regional and tariff-related dynamics underscore the importance of strategic sourcing, local manufacturing partnerships, and adaptive pricing frameworks. Leading companies are differentiating through portfolio diversification, R&D alliances, supply chain digitization, and capacity expansions. To capitalize on these trends, industry leaders should implement donor engagement strategies, pursue innovative contracting models, and harness predictive analytics for supply continuity. Altogether, this synthesis of findings and strategic perspectives provides a roadmap for stakeholders seeking to navigate the complex hyperimmune globulin landscape and deliver high-impact therapeutic solutions.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • Application
    • Prophylaxis
      • Cytomegalovirus
      • Hepatitis B
      • Rabies
      • Tetanus
    • Treatment
      • Cytomegalovirus
      • Hepatitis B
      • Rabies
      • Tetanus
  • Product Type
    • Equine
    • Human
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • LFB S.A.
  • Biotest AG
  • GC Biopharma Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Bio Products Laboratory Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of hyperimmune globulins for treatment of emerging viral diseases like COVID-19 and Ebola
5.2. Strategic partnerships between plasma collection centers and biotech companies to scale hyperimmune production capacity
5.3. Regulatory approvals of rHuPH20-facilitated subcutaneous immunoglobulin for improved hyperimmune delivery
5.4. Rising demand for equine-derived antivenom globulins driven by global snakebite incidence in rural regions
5.5. Development of monoclonal hyperimmune therapies as precision alternatives to traditional plasma-derived products
5.6. Expansion of hyperimmune prophylaxis use among immunocompromised patients for cytomegalovirus and RSV protection
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hyperimmune Globulins Market, by Route Of Administration
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous
8.4. Subcutaneous
9. Hyperimmune Globulins Market, by Application
9.1. Introduction
9.2. Prophylaxis
9.2.1. Cytomegalovirus
9.2.2. Hepatitis B
9.2.3. Rabies
9.2.4. Tetanus
9.3. Treatment
9.3.1. Cytomegalovirus
9.3.2. Hepatitis B
9.3.3. Rabies
9.3.4. Tetanus
10. Hyperimmune Globulins Market, by Product Type
10.1. Introduction
10.2. Equine
10.3. Human
11. Hyperimmune Globulins Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Hyperimmune Globulins Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
13. Americas Hyperimmune Globulins Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hyperimmune Globulins Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hyperimmune Globulins Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Grifols, S.A.
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Kedrion S.p.A.
16.3.6. LFB S.A.
16.3.7. Biotest AG
16.3.8. GC Biopharma Co., Ltd.
16.3.9. Shanghai RAAS Blood Products Co., Ltd.
16.3.10. Bio Products Laboratory Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HYPERIMMUNE GLOBULINS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HYPERIMMUNE GLOBULINS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HYPERIMMUNE GLOBULINS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HYPERIMMUNE GLOBULINS MARKET: RESEARCHAI
FIGURE 26. HYPERIMMUNE GLOBULINS MARKET: RESEARCHSTATISTICS
FIGURE 27. HYPERIMMUNE GLOBULINS MARKET: RESEARCHCONTACTS
FIGURE 28. HYPERIMMUNE GLOBULINS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HYPERIMMUNE GLOBULINS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY EQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 102. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 103. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 104. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 105. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 115. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 116. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 117. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 118. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 119. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 188. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 189. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 190. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 191. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. GERMANY HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 200. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 201. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 202. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 203. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 204. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 205. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. FRANCE HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 230. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 231. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 232. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 233. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ITALY HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 242. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 243. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 244. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 245. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 246. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 247. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SPAIN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 298. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 299. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 300. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 301. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 302. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 303. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 304. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 305. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. DENMARK HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 313. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 314. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 315. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 316. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 317. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 318. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 319. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. NETHERLANDS HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 325. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 326. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 327. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 328. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 329. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 330. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 331. QATAR HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 332. QATAR HYPERIMMUNE GLOBULINS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hyperimmune Globulins market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • LFB S.A.
  • Biotest AG
  • GC Biopharma Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Bio Products Laboratory Limited

Related Reports

Human Hyperimmune Globulins Market by Product Type (Cytomegalovirus Immunoglobulin, Hepatitis B Immunoglobulin, Rabies Immunoglobulin), Application (Post-Exposure Prophylaxis, Therapeutic Use), End User, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Human Hyperimmune Globulins Market by Product Type (Cytomegalovirus Immunoglobulin, Hepatitis B Immunoglobulin, Rabies Immunoglobulin), Application (Post-Exposure Prophylaxis, Therapeutic Use), End User, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Hyperimmune Globulin Injection Market by Indication (Diphtheria, Hepatitis B, Rabies), Application (Prophylactic, Therapeutic), Route of Administration, End User, Distribution Channel, Packaging Type - Global Forecast 2025-2030 - Product Image

Hyperimmune Globulin Injection Market by Indication (Diphtheria, Hepatitis B, Rabies), Application (Prophylactic, Therapeutic), Route of Administration, End User, Distribution Channel, Packaging Type - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Hyperimmune Globulins Market Report 2025 - Product Image

Hyperimmune Globulins Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Blood Plasma Derivatives Market Report 2025 - Product Image

Blood Plasma Derivatives Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Blood Plasma Derivatives Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033 - Product Image

Blood Plasma Derivatives Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.